Clinical significance of anti-Yt(b). Report of a case using a 51chromium red cell survival study.
Several published reports have documented the variable survival of Yt(a+) red cells (RBC) in patients with anti-Yt(a) as measured by 51Chromium (Cr)-labeled RBC survival studies. Similar studies with anti-Yt(b) have not been reported. A 51Cr-labeled RBC survival study was performed using Yt(b+) RBCs and a monocyte monolayer assay in a young hemodialysis patient who required chronic transfusion therapy and who had developed anti-Yt(b). The survival of the transfused RBCs was 100 and 93 percent at 1 and 24 hours, respectively, with a half life of 21 days at termination of the study (normal, 28 to 32 days). These results showed no evidence of rapid destruction of the Yt(b+) RBCs, indicating that this patient could be transfused safely with blood from Yt(b+) donors. Long-term survival of the 51Cr-labeled Yt(b+) RBCs was shortened moderately, however, a finding that correlated with a slightly abnormal monocyte monolayer assay test.
Levy
G J
GJ
Taft B. Schreiber Blood Bank, Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California.
Selset
G
G
McQuiston
D
D
Nance
S J
SJ
Garratty
G
G
Smith
L E
LE
Goldfinger
D
D
D000328:Adult; D001789:Blood Group Antigens / Q000276:immunology*; D001803:Blood Transfusion; D002470:Cell Survival; D002860:Chromium Radioisotopes; D004912:Erythrocytes / Q000166:cytology*; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000628:therapy; D016030:Kidney Transplantation
D001789:Blood Group Antigens; D002860:Chromium Radioisotopes